GFT505 Reduces the Risk of Cardiovascular Events

News   May 17, 2013

 
GFT505 Reduces the Risk of Cardiovascular Events
 
 
 

RELATED ARTICLES

FoxO Proteins Implicated in Arthritis Age Risk

News

A study examining osteoarthritis has shown that as joints age, levels of FoxO decrease, causing pain and inflammation.

READ MORE

Lonza to Establish Cell- and Gene-Therapy Centers of Excellence to Accelerate Growth

News

Lonza will establish Centers of Excellence for Cell and Gene Therapy to support and accelerate the growth of this priority area for the company.

READ MORE

Catalyst Biosciences Announces Positive Top-Line Data for Potential Hemophilia B Treatment

News

All individuals with severe hemophilia improved to mild hemophilia activity levels after only six daily doses with a continuous linear increase in Factor IX clotting activity. These results suggest that long-term dosing of SQ CB 2679d has the potential to maintain stable clotting activity in the high-mild hemophilia to normal range.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE